| 6.24 0.065 (1.05%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.53  |
1-year : | 8.79 |
| Resists | First : | 6.44 |
Second : | 7.53 |
| Pivot price | 5.73 |
|||
| Supports | First : | 5.21 |
Second : | 4.44 |
| MAs | MA(5) : | 6.03 |
MA(20) : | 5.49 |
| MA(100) : | 5.38 |
MA(250) : | 4.1 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 87.8 |
D(3) : | 83 |
| RSI | RSI(14): 62.8 |
|||
| 52-week | High : | 8.39 | Low : | 1.57 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ANNX ] has closed below upper band by 22.3%. Bollinger Bands are 4.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.45 - 6.47 | 6.47 - 6.49 |
| Low: | 6.05 - 6.07 | 6.07 - 6.09 |
| Close: | 6.2 - 6.23 | 6.23 - 6.27 |
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Sun, 21 Jul 2024
Annexon (NASDAQ:ANNX) Trading 3.9% Higher - Defense World
Mon, 15 Jul 2024
Annexon, Inc. (NASDAQ:ANNX) Short Interest Update - Defense World
Sat, 29 Jun 2024
Are Analysts Bullish on Annexon, Inc. (ANNX) Right Now? - Yahoo Finance
Fri, 07 Jun 2024
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Wed, 05 Jun 2024
Annexon Announces Pricing of $125 Million Underwritten Public Offering - GlobeNewswire
Tue, 04 Jun 2024
Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place (ANNX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 105 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 95.8 (%) |
| Shares Short | 5,160 (K) |
| Shares Short P.Month | 7,280 (K) |
| EPS | -1.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.9 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.7 % |
| Return on Equity (ttm) | -50.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -116 (M) |
| Levered Free Cash Flow | -74 (M) |
| PE Ratio | -4.28 |
| PEG Ratio | -0.2 |
| Price to Book value | 2.15 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|